Azacitidine for Injection a form of cancer that leads to one or more blood cell types dropping to low numbers.
| MANALAPAN, N.J., Nov. 19, 2018 /PRNewswire/ -- Armas Pharmaceuticals Inc. (Armas), a NJ based multisource pharmaceutical corporation, is announcing the launch of their first injectable to the U.S. market, Azacitidine for Injection 100 MG. Azacitidine for Injection, a generic to Vidaza®, is used for treating myelodysplastic syndrome, a form of cancer that leads to one or more blood cell types dropping to low numbers. Azacitidine, an oncology injectable, has an approximate market size of $116 million annually. Armas expects to launch nine or more generic injectable and oral products through the 1st quarter of 2019, with a market size totaling more than $430 million annually. “We are pleased to launch our first product in the U.S. market. This will be the first of a number of high-quality pharmaceutical products that we will launch in the Armas Pharmaceutical label through our partnerships. With Armas’s strong customer base and our outstanding partners, I have no doubt that Armas Pharmaceuticals will bring exceptional value with our upcoming product launches to healthcare professionals,” says John Niemi, President & CEO of Armas. About Armas Pharmaceuticals, Inc. Armas Pharmaceuticals is a generic pharmaceutical company delivering an ever-growing portfolio of high-quality products that provide convenience, affordability and consistency. Through the development of strong partnerships and industry relationships, Armas maintains this pipeline of products with customer and patient satisfaction in mind. Headquartered in Manalapan, New Jersey, Armas Pharmaceuticals is always open to new partnership opportunities and ways to offer our customers the best products at affordable prices. For more information, please visit ArmasPharmaceuticals.com. Contact:
SOURCE Armas Pharmaceuticals |
View original content to download multimedia:
